Crescendo

Five years after its founding, and less than one year after launching its first product, molecular diagnostics firm Crescendo Bioscience is shifting to full commercialization mode for its test targeting rheumatoid arthritis. Read More

Crescendo Bioscience has completed a $31 million Series C equity financing and entered into a strategic investment agreement with Myriad Genetics for $25 million, raising a total of $56 million. Read More

Myriad Genetics made a $25 million investment in Crescendo Bioscience , securing an exclusive, three-year option to acquire the company. Read More

SEATTLE--( BUSINESS WIRE )-- F5 Networks, Inc. (NASDAQ: FFIV), the global leader in Application Delivery Networking (ADN), today announced that it has acquired the intellectual property assets of Crescendo Networks. Read More

On March 1, officials decided to begin the lengthy revocation process against Crescendo, after allegations circulated that Crescendo founder and executive director John Allen ordered principals and teachers to use actual test questions to prepare students for the 2010 state standardized tests. Read More